2023
Master transcription factor reprograming unleashes selective translation promoting castration resistance and immune evasion in lethal prostate cancer.
Santasusagna S, Zhu S, Jawalagatti V, Carceles-Cordon M, Ertel A, Garcia-Longarte S, Song W, Fujiwara N, Li P, Mendizabal I, Petrylak D, Kelly W, Reddy E, Wang L, Schiewer M, Lujambio A, Karnes J, Knudsen K, Cordon-Cardo C, Dong H, Huang H, Carracedo A, Hoshida Y, Rodriguez-Bravo V, Domingo-Domenech J. Master transcription factor reprograming unleashes selective translation promoting castration resistance and immune evasion in lethal prostate cancer. Cancer Discovery 2023, 13: 2584-2609. PMID: 37676710, PMCID: PMC10714140, DOI: 10.1158/2159-8290.cd-23-0306.Peer-Reviewed Original ResearchConceptsLethal prostate cancerProstate cancerCastration resistanceImmune evasionPharmacologic targetingAnti-PD-1 therapyMajor histocompatibility complex IDeprivation therapyMicrophthalmia transcription factorAndrogen receptorPreclinical modelsTherapeutic strategiesCancerTherapyDruggable mechanismMaster transcription factorTranscription factorsKey mRNAsSpecific mRNAsMRNAFactor 3bEvasionSelected ArticlesTargetingTumors
2020
Efficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses.
Shore N, Armstrong A, Szmulewitz R, Petrylak D, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Rosbrook B, Lee H, Haas G, Stenzl A. Efficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses. Journal Of Clinical Oncology 2020, 38: 5547-5547. DOI: 10.1200/jco.2020.38.15_suppl.5547.Peer-Reviewed Original ResearchRadiographic progression-free survivalEfficacy of enzalutamideAndrogen deprivation therapyMetastatic hormone-sensitive prostate cancerSymptomatic skeletal eventsSoft tissue metastasesMetastatic spreadVisceral metastasesSecondary endpointsBone metastasesFirst symptomatic skeletal eventHormone-sensitive prostate cancerProstate-specific antigen progressionLarge patient subgroupPrior docetaxel treatmentProgression-free survivalSecondary endpoint measuresGreater relative efficacyNew antineoplastic therapiesM0 patientsDeprivation therapyPrimary endpointSkeletal eventsCastration resistanceDisease volume